Nighttime
NDC Package 51672-2113-7

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Nighttime is a . Marketed by Taro Pharmaceuticals U.s.a. Inc., this product is identified by NDC 51672-2113 and is authorized under FDA application part341.

Identification & Billing

NDC Package Code
51672-2113-7
Package Description
6 POWDER, FOR SOLUTION in 1 CARTON
Product Code
51672-2113
11-Digit Billing Format
51672211307

Clinical Specifications

Proprietary Name
Nighttime Flu And Severe
Dosage Form
-

Regulatory & Marketing

Labeler Name
Taro Pharmaceuticals U.s.a. Inc.
FDA Application #
part341
Marketing Category
OTC MONOGRAPH FINAL - A product marketed pursuant to a final Over-the-Counter (OTC) Drug Monograph.
Start Marketing Date
06-28-2013
End Marketing Date
01-17-2020
Listing Expiration
01-17-2020
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51672-2113-7 identifies a specific commercial package of 6 powder, for solution in 1 carton of Nighttime Flu And Severe, labeled by Taro Pharmaceuticals U.s.a. Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Taro Pharmaceuticals U.s.a. Inc. on June 28, 2013. The current certification is valid through January 17, 2020.

How is this Taro Pharmaceuticals U.s.a. Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51672211307. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51672-2113-7
11-Digit CMS (5-4-2)
51672-2113-07

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.